Early diagnosis is critical to improve outcomes in rheumatoid arthritis (RA), but current diagnostic tools have limited sensitivity. Here we report a large-scale multicenter study involving training and validation cohorts of 3,262 participants. We show that serum levels of soluble scavenger receptor-A (sSR-A) are increased in patients with RA and correlate positively with clinical and immunological features of the disease. This discriminatory capacity of sSR-A is clinically valuable and complements the diagnosis for early stage and seronegative RA. sSR-A also has 15.97% prevalence in undifferentiated arthritis patients. Furthermore, administration of SR-A accelerates the onset of experimental arthritis in mice, whereas inhibition of SR-A ameliorates the disease pathogenesis. Together, these data identify sSR-A as a potential biomarker in diagnosis of RA, and targeting SR-A might be a therapeutic strategy.
文章引用产品列表
-
- CS0001
- 刺激阻断剂
Phorbol 12-Myristate 13-Acetate(PMA,佛波酯)
- ¥170.00 – ¥800.00
-
- CS0002
- 刺激阻断剂
Ionomycin Calcium(离子霉素)
- ¥460.00 – ¥4,460.00
-
- CS0003
- 刺激阻断剂
Brefeldin A(BFA)布雷非德菌素A
- ¥460.00